Celltrio, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation.

Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs.